Chinese Firms At JPM Not About China, It’s Time To Go Global
From Specialized Biotech To Global Biopharma In Decade
From BeiGene to Innovent to Wuxi Biologics, executives at Chinese pharma firms are now discussing collaborations to go beyond China to become biopharma operations with a truly global presence.
You may also be interested in...
China's drug regulatory authority is taking aim at strengthening randomized, controlled clinical trials conducted domestically for cancer drugs, leaving biotech stocks reeling from the proposed stricter requirements.
Beijing’s latest proposal to ban gene editing is viewed as a direct response to Washington’s tightening grip over the transfer of US technology to China.
The latest surveillance balloon downing could torpedo improving bilateral health collaboration between China and the US at a time when warming ties are crucial to solving a flurry of gridlocks.